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ABSTRACT
DIFFUSIVITY OF DRUG ACTIVES IN TRANSDERMAL DRUG DELIVERY
(TDD)
by
Natali R. Gendelberg
Transdermal Drug Delivery (TDD) through skin patches has many advantages including
the following: slow and continuous administration of the therapeutic over long periods of
time, timely dosage, accessibility, kinetic maneuverability, elimination of the “First Pass
Effect” and negative side effects on the digestive tract. All of the above justify investment
into further development of TDD therapies, despite the skin permeability restrictions posed
on size and charge by the skin. As skin permeability varies between all individuals based
on age, ethnicity and lifestyle, the determination of the proper drug dosages to be contained
in the skin patch is highly reliant on clinical trials. The objective of this research is to
further investigate the application of components of a modified Duda-Zalinsky Equation
(DZE) for drug diffusivity through a polymer matrix, to account for physical enhancers
added to the Heated Lidocaine-Tetracaine Patch based on diffusivity results obtained from
tests run in a Franz Cell apparatus. Pre-clinical trials computational estimation of the drug’s
diffusion properties with respect to the polymer matrix and skin will provide for safer
clinical trials, with testing dosages that are closer to the therapeutic drug concentration in
the blood.
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CHAPTER 1
INTRODUCTION

1.1 Objective
The focus of this research is to examine a computational method for estimating the
diffusivity of a drug diffusing through a polymer matrix, such as that found in a skin patch
with additional physical diffusion enhancers. Components of a modified Duda-Zalinsky
Equation (DZE) [1] for molecular diffusivity through a polymer matrix will be considered
to assess the impact of a heat enhancement. The physical enhancement incorporated into
the Synera Heated Lidocaine/Tetracaine patch (a local anesthetic manufactured by Galen
Inc.) is considered within this context. The energy and viscosity values obtained
computationally will be compared with diffusivity results obtained from tests performed
on the patch in a Franz-Cell apparatus [2-10]. Such pre-clinical trials and computational
analysis of the diffusion characteristics of the drug will allow for proper dosage of the skin
patches, thereby reducing the risk involved in clinical trials.

1.2 Skin Anatomy
The skin is the largest organ in the human body, with the primary purpose of preventing
the entrance of foreign invaders. Additionally, the skin serves as a tool for body
temperature adjustment and for sensory purposes. The skin’s three primary layers are, from
top to bottom, the epidermis, dermis and hypodermis that mainly contains subcutaneous
fatty tissue (Figure 1.1). The cells that make up the skin are called keratinocytes, due to
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their increased production of the protein keratin that protects these epithelial cells from
damage due to exterior stresses [11].

Figure 1.1 Skin anatomy with a close up of the SC and drug diffusion paths in the inset.
"Human Skin Anatomy Diagram." Human Anatomy Body Picture.
Benita S. Submicron Emulsions in Drug Targeting and Delivery.

The epidermis consists of the stratum corneum (SC), a pigment layer and at the
interface with the stratum basale of the dermis – the stratum spinosum. The stratum
spinosum consists of basal cells that interlock with the dermal papilla that stick out of the
stratum basale. Sweat pores that allow for water evaporation for body temperature
mediation can be found on the surface of the SC. Sweat glands are located in the
hypodermis, but are connected to the sweat pores and extend through all skin layers. The
hair shaft extends out of the SC from the hair follicle that extends into the hypodermis,
with the papilla of the hair located in the hypodermis. Each hair follicle contains sebaceous
glands on its side, which secrete oil into the hair follicle in order to prevent the hair shaft
from becoming brittle [11].
The skin performs several sensory functions. The dermis holds nerve endings closer
to the interface of the epidermis and the dermis and extend into the hypodermis, thus giving
them sensitivity to touch on the surface of the skin. The Pacinian corpuscles are nerve
receptors embedded in the hypodermis and detect pressure and vibration. Arrector pili
2

muscles attached to the hair follicles are controlled by the sympathetic nervous system to
contract and further insulate the skin, which causes rising of the hair shaft. Dispersed nerve
endings extending throughout skin layers, blood and lymph vessels (located in the
hypodermis) and hair follicles serve to detect and amplify sensory response [11].
This research is primarily focused on the SC, as it is the rate limiting step in TDD
diffusion. As can be seen in the inset in Figure 1.1, the SC has a “brick and mortar”
infrastructure. This brick-like characteristic is due to the ordering of the corneocytes that
are linked via corneodesmosones, while the mortar-like characteristic is due to the lipid
medium in between the corneocytes. Corneocytes are “dead” keratinocytes that are filled
with keratin and engulfed in a cornified envelope of lipids and surrounded by a lipid filler.
This foundation of the SC allows for only two paths for drug diffusion: directly through
the corneocytes and lipids or solely through the surrounding lipid paths. These conditions
provide both charge and size restrictions on the penetrant. In order to diffuse through the
SC, the drug must be neutral and must abide by the “500 Da Rule”. The “500 Da Rule” is
primarily based on clinical results and analysis of natural skin penetrants, which show that
only molecular compounds or drugs with molecular weight less than 500 g/mol can freely
diffuse through the SC [14].

1.3 TDD Market
The TDD market was valued at approximately $27 billion in 2013 and was predicted to
experience an 8% Compound Annual Growth Rate (CAGR) for the five years following
the publication of this report [16]. Local anesthetic patches have undergone several
upgrades over the years, despite their constituting only 2% of the global TDD market
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(Figure 1.2) [17]. Part of the interest in investment into local pain relief patches is to control
usage of such therapeutics as they are controlled substances that may cause addiction.
Furthermore, slow release patches are more effective than bolus doses that fluctuate.
TDD GLOBAL PRODUCT SALES BY SEGMENT
Nitroglycerin
27%

Fentanyl
31%

Nicotine
7%

Clonidine
6%

Estradiol Combo
2%
Estradiol
14%

Scopolamine
1%
Tulobuterol
4%

Local Pain
Patches
2%

Testosterone
6%

Figure 1.2 Global TDDS sales by segment.
B. Debjit, S. Duraivel, and K. P. .Sampath Kumar. "Recent Trends in Challenges and Opportunities in
Transdermal Drug Delivery System." The Pharma Innovation 1.10 (2012): 9-23. Web.

Targeted drug delivery and sustained release drugs (Figure 1.3) are shown in the
bar graph for market value of oral drugs. Sustained release drugs do not solely represent
skin patches, which explains the increased value of the market sector, compared to the
value reported in the previous paragraph. The key growth trends, observed in this depiction,
between 2004-2011 are: a 2.5x increase for transmucosal drug delivery, a 5x increase for
targeted drug delivery and a 1.8x increase for sustained release, implants and TDD. The
former value can seem unnerving, compared to the increase in value associated with
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targeted drug delivery. This drastic difference is due to several factors. First, targeted drug
delivery technologies experienced a significant breakthrough between the years 20062011, before which sustained release, implants and TDD dominated the therapeutics
market as its primary constituent. Second, sustained release, implants and TDD still
encompass almost half of the therapeutics market. Third, many targeted drug delivery
technologies utilize TDD and sustained drug release. Therefore, the extreme increase could
be due to intermarket overlap. The increase in market value of transmucosal therapies does
not signify a potential profit. The drug market percentage represented by transmucosal
drugs decreased by 2% and began at a substantially lower value compared to other
therapies.

Figure 1.3 Drug delivery market trends.
S. Kumar, K. P., D. Bhowmik, B. Chiranjib, and R. M. Chandira. "Transdermal Drug Delivery System A Novel Drug Delivery System and Its Market Scope and Opportunities." International Journal of
Pharma and Bio Sciences 1.2 (2010): 1-21. Web.
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1.4 Advantages of TDD
Transdermal drug delivery has a slow and continuous drug release profile. This sort of
profile is ideal for treatments involving drugs with a short half-life that must be
administered frequently over long periods of time. The patch’s constant presence also
ensures timely dosages that prevent unwanted variations in the drug’s blood concentration.

Figure 1.4 Cycle of blood concentration with respect to time in TDD.

The skin’s large surface area makes skin patches a highly accessible, yet noninvasive and kinetically maneuverable form of treatment. As can be seen in Figure 1.4, oral
and bolus drug administration involve fluctuations of the drug concentration in the blood,
with a spike at the time of administration and a sudden decrease at peak concentration. In
order to obtain an average dosage around the middle of the therapeutic range, the initial
dosage must be much higher. Each valley-to-valley segment of Figure 1.4 represents a
single administration. From this representation, it is evident that such treatment involves
cyclical dosage fluctuations whose range varies between individuals based on weight, age,
life-style and genetics. Therefore, for different individuals, the valleys and peaks of the
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drug administration may exceed or fall below the toxic and minimal therapeutic drug
concentrations, respectively [19].
The oral/bolus forms of drug administration set up a precedent where a patient is at
risk or is not receiving effective treatment at a certain fixed time, which can also bring
upon a set of side effects such as nausea. In contrast, the skin patch maintains a quite
consistent dosage that can be tailored by modification of the polymer matrix through which
the drug diffuses. Application time of the patch is determined based on the point at which
the drug remaining in the patch reservoir provides for the determined margin of decrease
in resulting blood concentration. Furthermore, administration can be instantaneously halted
via patch removal in the case of evident deleterious side effects.

Figure 1.5 Illustration of the “First Pass Effect”.
"First Pass and Plasma Drug Levels (Introduction) (Human Drug Metabolism)." Whatwhenhow RSS.
Web. 03 Feb. 2016.

The ability of the skin patch to circumvent passage through the gastrointestinal tract
(GIT) has two advantages: 1) the drug does not damage the GIT or its mucus membrane
and 2) the “First Pass Effect” is eliminated. The “First Pass Effect” (Figure 1.5) is a result
of the body’s clearance system. After entering the stomach, the drug may be detected and
cleared out by the body as a foreign object in passage through the intestines and the liver,
resulting in a reduced dose entering the blood stream where the drug undergoes another
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series of clearance. This requires that the initial dosage administered to the patient be much
higher than the therapeutic dosage. As the amount of drug cleared out varies between
individuals, as mentioned above, this may result in varying side effects that cannot be
halted without complete clearance that is physiologically controlled [20].

1.5 Limitations of TDD
The skin’s foundation is built on preventing the entrance of any foreign objects into the
body. As such, the charge and size limitations, discussed in the skin anatomy section,
eliminate the design of skin patches for a large scope of therapeutics, including: gene
therapy, liposomal drug delivery and charged particles. As an individual’s lifestyle impacts
metabolic activity, while SC thickness and skin composition varies in different parts of the
body and between individuals, the theoretical blood dosage with respect to polymer matrix
design varies between individuals and is highly reliant on clinical trials. As a result, skin
patch dosages are determined based on clinical trial results and thus pose high risk to the
subject as the resulting dosage may fall in an individual’s toxic dosage. Finally, skin
adhesives may cause skin irritation and rash [1, 22].
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CHAPTER 2
BACKGROUND

2.1 Basic Skin Patch Construct
The two primary types of skin patches are: the reservoir patch and the matrix patch (Figures
2.1 and 2.2, respectively). The main difference between these types of patches is their form
of drug storage and kinetics. The patch acts as an initial drug reservoir. Once the patch is
placed at the site of application, the drug begins to diffuse into the SC due to osmotic
pressure and forms a secondary reservoir in the SC, which further emphasizes the SC’s rate
limiting property. The drug diffuses through the SC into capillaries, present in the
hypodermis and thereby enters the blood stream [23].

Figure 2.1 Cross-section through a reservoir patch.
Margetts L. and Sawyer R. "Transdermal Drug Delivery: Principles and Opioid Therapy." Contin Educ
Anaesth Crit Care Pain Continuing Education in Anaesthesia, Critical Care & Pain 7.5 (2007): 171-76.

Figure 2.2 Cross-section through a matrix patch [23].
Margetts L. and Sawyer R. "Transdermal Drug Delivery: Principles and Opioid Therapy." Contin Educ
Anaesth Crit Care Pain Continuing Education in Anaesthesia, Critical Care & Pain 7.5 (2007): 171-76.
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The reservoir patch contains the drug in liquid form in a reservoir on top of a
polymer membrane interface, which acts as the rate limiting component of drug release
from the patch itself. This feature allows for greater control of the drug delivery rate by
varying the polymer membrane composition, conformation and constituents. Despite the
increased control over the diffusion rate, an initial burst of the drug may occur due to the
large concentration difference between the drug reservoir and SC as the SC initially has
yet to form its own drug reservoir. Furthermore, any inconsistency in the polymer
membrane thickness may pose as a site of increased diffusion rate that may cause an
overdose. In the matrix patch, the drug is evenly distributed in the adhesive polymer matrix,
with the drug diffusion rate limiting factors being the amount of drug held in the polymer
matrix, the formulation of the polymer matrix and the area of the patch applied to the skin
[23].

2.2 Governing Diffusion Equations
Diffusion involves the movement of particles from regions of high concentration to regions
of low concentration via random movement. Diffusion whose driving force is solely the
concentration gradient between regions in the volume of diffusion is referred to as passive
diffusion, with the movement of the diffusing particles following the “Random Walk”
model or probability function. This type of diffusion is quite slow with a well-defined
direction. In some cases, where diffusion must occur faster or against a concentration
gradient (i.e., to trigger another process), a convective factor is added to the diffusion in
the form of additional energy or physical barriers. In 1855, Adolf Fick derived the most
basic governing diffusion equation [24].
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(2.1)

The flux J represents the amount of particles diffusing through a cross sectional
area perpendicular to the path of diffusion. Fick’s First Law of Diffusion provides
information on the expected amount of flux. Figure 2.3 shows that the flux is proportional
to the diffusivity of the particle, D, which accounts for the tendency of the particle to diffuse
through the medium. The concentration gradient, dC/dx, generates the energy that causes
the particles to diffuse from areas of high concentration to areas of low concentration. The
negative sign in equation (2.1) signifies the increase in flux in the direction of decreasing
concentration [24].

Figure 2.3 Fick’s 1st Law plotted in terms of the flux with respect to the concentration
gradient.
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(2.2)

Fick’s Second Law of Diffusion (equation (2.2)) provides information regarding
the rate of change of concentration at any point in space. The left side of the equation, the
gradient of the concentration with respect to time, is directly related to the Laplacian of the
concentration with respect to distance from the cross section through which the particles
diffuse.

Figure 2.4 Fick’s 2nd Law plotted in terms of the flux with respect to the distance from
the cross sectional area perpendicular to the path of diffusion.
Figure 2.4 depicts this relationship in which the flux approaches zero with
increasing distance from the cross sectional area being analyzed, regardless of the distance
being in front or behind the cross sectional area. As the distance to the cross sectional area,
perpendicular to the path of diffusion, approaches zero from the positive direction, the flux
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goes to infinity. Conversely, as the distance to the cross sectional area, being discussed, is
reduced in magnitude from the negative direction, the flux approaches negative infinity
[24].
Steady-state diffusion is diffusion that is not time dependent. In contrast,
nonsteady-state diffusion is time dependent and exhibits varying diffusion profiles at
varying time points. Fick’s second law of diffusion is primarily used for nonsteady-state
diffusion profiles as it contains a time dependent term. In analysis of steady-state diffusion,
the gradient of concentration with respect to time term is equal to zero.

2.3 Diffusion Through Skin
In order for diffusion to be feasible and predictable in a noninvasive manner, the drug’s
diffusivity needs to be estimated. The simplest calculation for molecular diffusivity is given
by the Stokesian Diffusion, in which a spherical particle with radius r diffuses through a
continuous fluid medium (equation (2.3)). The numerator of the Stokes-Einstein equation
accounts for the positive contribution due to particle diffusion in terms of absolute
temperature (T) and the Boltzmann constant (k), whereas the denominator emphasizes that
increasing particle size (r) and viscosity (µ) poses a hindrance for diffusion. The viscosity
plays a significant role because each individual particle gets engulfed by a static layer of
the fluid medium. This results in a friction between the static layer and the fluid medium
moving relative to the diffusing particle [25].
(2.3)
6
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Aside from the direct temperature correlation seen in equation 2.3, there is a hidden
exponential temperature factor that contributes to the particle diffusivity that is hidden in
the temperature dependence of viscosity. Evidence of this dependence is visible in
equation (2.4), Joback’s equation for viscosity, which correlates the liquid dynamic
viscosity (µL, units: Pa·s) to the sum of constant viscosity factors per bond group in the
molecule (µa and µb) and the temperature (T). The division of bond segments in the
molecule refers to carboxyl bonds, double bonds, bonds that are part of an aromatic ring
etc. This equation is valid between the melting temperature of the molecule and 0.7 times
its critical temperature, i.e., the temperature at which the gas form of the molecule can no
longer condense back into solution [25]. Viscosity decreases with temperature
exponentially because more molecules obtain sufficient energy to overcome the resistive
shearing forces that hinder diffusion or movement. Also, greater particle mobility results
in a higher level of disorder that thins out the liquid. The Stokes-Einstein diffusivity does
not consider particle shape; it contains two particle size factors – the radius in the
denominator and the molecular weight in the viscosity calculation.

∑

.

∑

.

(2.4)

More often than not, the geometry of the particle diffusing or the nature of the
medium results in Non-Stokesian Diffusion. Large particles that are arranged in chains or
complex geometries, i.e., polymers, proteins etc., may change geometry as a result of the
attractive forces between the medium and side groups, may have their center of gravity in
a nonsymmetrical position along their length and may diffuse in different directions. This
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results in more complex diffusion patterns that are dependent on the available free
volume/holes that can accommodate the movement, geometry and molecular properties of
the diffusing particles with respect to their matrix.
As the polymer membrane through which the drug active diffuses in the patch is
not a fluid, the Stokes-Einstein parameters are breached. Furthermore, the cell membrane
exhibits anisotropic diffusion/penetration properties. The fluid in the plane of the
membrane results in transverse particle diffusion through the fluid. In one form of diffusion
through the SC, lateral diffusion or transmembrane diffusion, the diffusing particle is set
back by the hydrocarbon chains that are vertically anchored. In the second form of diffusion
through the SC matrix (around the corneocytes), there are physical hindrances that lead to
loss of energy to the particle and results in a smaller diffusivity. The “brick and mortar”
structure of the SC prevents transmembrane diffusion and facilitates increased diffusion
path length. Therefore, in both processes of diffusion through the skin patch membrane and
the skin, the diffusion of the drug is Non-Stokesian [25].
Non-Stokesian diffusivity computations vary based on diffusion characteristics.
They normally involve adding an exponential multiplier to the Stokes-Einstein equation
that accounts for the system’s deviation from Stokesian Diffusion. In the case of particles
diffusing through a polymer membrane and the SC, analysis via the free volume theory is
most adequate. This analysis involves an exponential factor that is a probability function
that computes the probability of the diffusant encountering a hole with the minimum
critical volume required for diffusion to occur. In this view, the particle and the hole are
viewed as mutually diffusing.
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Experiments performed to assess free hole volume in a hydrocarbon chain matrix,
which can be compared to the hydrocarbon tails of the cell membrane, showed that
approximately 35% of the total volume is attributed to free hole volume [26]. It is not
feasible to computationally calculate the exact free hole volume in a polymer matrix as it
accounts for the difference between the total volume of the matrix and the Van der Waals
volume of the polymers, which may vary with time as well. Therefore, the free hole volume
should be statistically based on the following premises: 1) it is most probable to encounter
small holes and 2) the formation of large holes is highly improbable. Thus, the diffusion
coefficient depends on the number of holes, the net hole formation frequency and the
probability of finding a hole as a function of the exponent of the ratio of the minimum hole
volume necessary for diffusion with respect to the average hole volume [25].

⁄

∗⁄

(2.5)

The basic probability function for diffusion through a polymer matrix is that posed
by Vrentas and Dudas for the infinite particle diffusivity, as can be seen in equation (2.5).
The term D0 refers to the Stokes-Einstein diffusivity (equation (2.3)). The first exponential
term accounts for the Arrhenius factor of the diffusion that is related to the kinetic energy
of the diffusing particle. This E term refers to the activation energy required for the drug
to overcome the attractive intermolecular forces with its medium in order to diffuse. T
refers to the temperature in Kelvin and k is the Boltzmann constant. The second exponential
term accounts for the ratio of the critical jumping volume required for diffusion with
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respect to the total available free volume (V*/V) multiplied by the ratio of the solvent to
polymer jumping unit that is determined by a factor of the occupied volume of the diffusing
molecule (subscript 1) and the polymer matrix (subscript 2) [1]. Table 2.1 emphasizes the
role of the shape of the diffusing molecule. It is evident that, for molecules of equal
volumes, the elongated molecules have a greater diffusivity. This phenomena is attributed
to the higher probability of the longer configuration of the molecule finding a hole that fits
its smaller cross section (the cross sectional area perpendicular to its length). This
directional diffusion property is referred to as reputation [25].

Table 2.1 Effect of the Shape of a Diffusing Molecule on Diffusion in a Polymer

Stein, Wilfred D., and W. R. Lieb. Transport and Diffusion across Cell Membranes. Orlando:
Academic, 1986, 94-102.
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2.4 TDD Penetration Enhancement Technologies
The purpose of investment into TDD penetration enhancement technologies is to improve
drug diffusion and to facilitate the utilization of TDD for a wider range of drugs, including
those that violate the charge and size barriers posed by the SC. The two categories of these
technologies are: physical penetration enhancers and physical methods of TDD. Physical
penetration enhancers include modifications to the SC to increase its permeability or its
electrochemical

character,

including:

Iontophoresis,

Electroporation

and

Ultrasound/Sonophoresis. Physical methods of TDD involve a more forceful
circumvention of the SC that might involve its local elimination; such methods include:
Hypodermic Needles, Jet Injections, Crystal Microdermabrasion, Thermal Ablasion, Laser
Ablasion and Microneedles [27].
A schematic of the construct of an iontophoretic system is shown in Fig. 2.5. The
system involved contains two electrodes that are in contact with the skin and extend out of
electrolyte chambers. One electrolyte chamber contains the drug along with anions (if the
drug is cationic, as in the figure), while the other chamber contains a buffer solution of
similar polarity.

Figure 2.5 Depiction of an Iontophoretic electroosmotic system on the ionic level.
Bhowmik, D., Duraivel, S. and Sampath Kumar, K.P. "Recent Trends in Challenges and Opportunities
in Transdermal Drug Delivery System." The Pharma Innovation 1.10 (2012): 9-23.
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A small electric current passing through the electrodes causes an electrical potential
across the skin. As this functions as an electroosmotic system, the solvent flows in the
direction of the ion movement and transports the cationic drug molecules through the skin.
The dosage results from the magnitude of the charge generated by the applied current. This
method generates better diffusion outcomes with cationic drugs because the cell membrane
potential is negative, with increase in cationic drug contribution to electroosmosis being
directly proportional to the molecular weight of the drug.

However, the skin’s

permselectivity can be modified via adjustment to the formulation’s pH, thereby promoting
diffusion in the direction of the anions and allowing this method to be applied to anionic
drugs as well. Additionally, increased ion mobility is preferable for decreased period of
current passage, as the electrolytes “compete” to a certain extent with the active agent as
charge carriers [28].
Despite osmosis generally being a passive form of diffusion, iontophoresis involves
convective diffusion as the therapeutics are repelled into the skin. This property results in
additional functions such as physiological monitoring by attraction of water soluble
molecules present in the interstitial fluid. Drug dosages can be fine-tuned to provide for
pulsatile drug delivery profiles that may prevent the body from becoming tolerant to the
therapeutic [27]. Iontophoresis requires strict current limitation to prevent erythema. This
method is not cost effective and was recalled by the European Medicine Agency due to
continuous fentanyl release resulting from corrosion products from the system components
when the device was deactivated, as well [22].
In electroporation, high voltage pulses are applied for a short duration to
specifically increase SC permeability in controlled areas, thereby increasing the possible
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diffusant size. The high-voltage electrical pulses disrupt the brick-and-mortar structure of
the SC, which physically increases its susceptibility for diffusion while causing
electrophoretic movement of the diffusing particles. This method provides promising in
vitro result when compared to other permeability enhancers, but in vivo skin toxicological
studies have yet to be sufficiently surveyed [22].
Ultrasound/Sonophoresis involves application of low frequency ultrasound to a
site of the SC to increase the percutaneous drug flux. The SC’s infrastructure is interrupted
with the formation of cavitational bubbles by the ultrasound’s oscillations. Sonication
devices can include additional features, such as real-time impedance feedback that provides
control over the activation of sonication with respect to the relevant conductance level.
Despite the ability to individually tailor this form of enhancement, it is not widely used as
its effect in humans is not sufficiently clear [22].
Hypodermic Needles that extend directly into the dermis are one of the most
commonly used physical methods of TDD, with the feature of delivering impermeating
and unstable compounds. This is achievable because the hypodermic needle acts as a piston
that applies quickly a high pressure force that administers a large bollus of the drug, at an
instant [29]. The controlled and continuous drug release that is desirable in TDD systems
can be obtained by placing indwelling catheters in the skin. This method perforates the
skin, thus making it invasive and a site of infection. In concept, Jet Injections are similar
to hypodermic needles as they use high-pressure accelerators that utilize helium to push
through either solid or liquid particles through the skin in a piston action. The advantage
of jet injections over hypodermic needles lies in their noninvasive property, but they cannot
facilitate long term drug release. Microscale microneedles are also used in a similar
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manner, but they are designed short enough to avoid excitation of nerve endings while
penetrating through the SC. Solid microneedles are used prior to the application of a skin
patch, as the holes created result in skin permeability increasing by four orders of
magnitude. Coating of the microneedles with the therapeutic allows for direct delivery of
the drug upon penetration of the microneedles [27].

Figure 2.6 Sketch of different types of microneedles and their application.
Wang, Binghe, Longqin Hu, and Teruna Siahaan. Drug Delivery: Principles and Applications. 2nd ed.
Wiley, 2005. Print. p. 217

Crystal microdermabrasion is a form of pretreatment to skin patch application. As
part of the local preparation for application of the patch, the skin is exfoliated by
microcrystals blown unto it. This treatment removes the CS, which has been shown to
successfully increase the net flux and diffusivity of low-molecular weight drugs through
the skin. Microdermabrasion is selectively designed to remove the SC only, while leaving
the rest of the epidermis layer intact [27].
Laser ablation involves shining laser beams unto the skin to create pores through
the SC that facilitate the diffusion of drugs that violate the charge and to some extent size
limitations on TDD. This form of diffusion enhancement may also serve to extract

21

physiological data from the patient, by drawing interstitial fluid from the pores created in
the SC. As laser ablation is a high-cost and complicated technology and this form of
treatment is not for a single use, it is not widely used. This form of enhancement is not
always performed a single time because the SC grows back and must be removed for
subsequent patch therapies, which shows the advantageous minimally destructive character
of this form of enhancement [22].
Thermal ablation works on the same premise as laser ablation, which is selective
removal of the SC without causing permanent damage to the skin and its infrastructure.
Heat is applied to the skin by an external heat source for a short amount of time, which
disrupts and removes the SC and creates microchannel structures in the skin. The resulting
microchannel structures are caused by three processes that occur as a result of the sharp
heat exposure: (1) the loss of the structural viability of the brick-and-mortar structure of
the SC; (2) the disruption of the keratin network within the SC; (3) the decomposition and
vaporization of keratin due to heat, which leaves behind microscale vacancies in the SC
[30].
It has been shown that the SC permeability is significantly increased with
increasing temperature during thermal ablation, rather than with heating time. This being
the case, there must be a strict control over the balance between effective temperature levels
and exposure time of the tissue below the SC to prevent permanent damage to the skin. Lee
et al. (2011) devised an apparatus to locally heat the skin for a duration of the order of 100
µs. This apparatus consists of water in a microchamber that is rapidly heated by discharging
electric current through it. By utilizing the conversion of electrical current to thermal and
mechanical energy in a localized manner, the generated jet of superheated steam is
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immediately ejected unto the skin. In order to validate the effectiveness and safety of this
construct, the authors [30] sought out to: (1) determine the heat transfer profile through the
skin to produce a protocol with the most effective and safe heat level with respect to
exposure time; (2) evaluate the efficacy of the microdevice in removing the SC, so as to
improve skin permeability to hydrophilic molecules and macromolecules [30].
Thermal ablation was performed at a temperature of 1100 °C and tested for 1 µs,
10 µs, 100 µs, 1 ms, 10 ms and 100 ms time durations. Thermal ablation was tested for
three levels of skin exposure: bare skin, skin covered by a heat conducting mask and skin
covered by a heat conducting mask covered by a window patterned insulating mask. The
skin exposed under latter conditions creates a perforated pattern on the SC, thereby
showing precision of localization of the thermal ablation process while leaving segments
of viable SC between the pores that can prevent infection and damage to future
development of the skin. The 100 µs ablation time provided for the best combination of
skin viability and increased permeability. The tested skin exhibited an increase of four and
three orders of magnitude in permeability to sulforhodamine and bovine serum albumin
(BSA), respectively [30].
Thermal ablation is a more economically favorable and safe method compared to
the other diffusion enhancement techniques, while significantly improving drug diffusion
and the breadth of drugs that may be used for TDD. It has been observed that properly
combining more than one enhancement technique may generate a synergistic effect,
pending the treatment or therapeutic characteristics. Combining electroporation with
sonophoresis results in two different types of disruptions to the SC structure
simultaneously, while electroporation also adds to electroporetic diffusion of the drug.
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When electroporation is combined with iontophoresis, the electroporation increases SC
permeability while iontophoresis adds a convective diffusion force to the diffusing
particles. A similar effect occurs when iontophoresis is combined with microneedle
treatments that provide direct access to the vascularized skin layers [22].

2.5 Impact of Heat on Diffusion
As was discussed in Section 2.3, equation (2.3) for particle diffusivity in a Stokesian system
experiences its temperature impact primarily from the viscosity term that exponentially
decreases with increasing temperature. This reduction in viscosity is primarily attributed
to increased particle energy and reduced molecular organization due to the addition of heat
to the system. As such, the Stokesian system’s activation energy is determined based on
the activation energy for the viscosity of the medium, which is determined by the increase
in free volume due to expansion with increasing temperature [25].
In a Non-Stokesian system, the increase in diffusivity with respect to temperature
is two-fold, resulting from: the increase in free volume and the increase in the overall rate
of formation of holes. This is expressed in equation (2.5), for the probability function
based diffusivity, in the exponential factor of the viscosity in the Stokesian diffusivity term
and in the exponential Arrhenius term. Furthermore, activation energy in diffusion through
a polymer matrix is greater than in diffusion through a liquid. Therefore, the temperature
contribution to the diffusivity for a Non-Stokesian system is of greater value. As can be
seen in Table 2.2, the type of polymer through which the particle is diffusing greatly
impacts the activation energy of the diffusing particle. As natural rubber is not galvanized,
the polymer strands slide past each other when undergoing tensile stress and allow for more
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open diffusion paths. On the other hand, polyisobutylene is a crosslinked butyl rubber that
makes it very resilient. This type of infrastructure contains more restricted diffusion paths,
similar to the brick-and-mortar structure exhibited in the SC [25].

Table 2.2 Activation Energy for Diffusion within Polymers

Stein, Wilfred D., and W. R. Lieb. Transport and Diffusion across Cell Membranes. Orlando:
Academic, 1986, 94-102.

2.6 Impact of Heat on Skin Permeability
In TDD, the drug crosses two diffusion membranes: the polymer matrix in the patch and
the SC with two different fluxes that are related to each other by the partition coefficient
of the aqueous solution of the drug in the reservoir with respect to the SC. Once the drug
partitions from the reservoir to the SC, it also partitions into the deeper levels of the skin
that can be termed aqueous, as well (Figure 2.7).
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Figure 2.7 Simplified model of diffusion starting from the patch reservoir, across the
polymer matrix and SC*.
* The dimensions of the SC are exaggerated compared to the skin patch reservoir.
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The flux of the drug diffusing from the reservoir to the deeper skin levels is related
to the product of the SC permeability (P) and the area (A) through which the drug is
diffusing (first part of equation (2.7)). As with previous flux calculations, this one is
proportional to negative concentration gradient (Caq,1 and Caq,2). The second form of the
flux equation substitutes the SC permeability for the ratio of the SC diffusivity (DSC) and
the diffusion path length (L). As can be seen from equation (2.6) for the partition coefficient
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of the SC, Km, the concentrations on the surface of the membranes on the aqueous sides
are related to the concentrations on the SC side of the membranes (CSC,1 and CSC,2). This
relationship is equivalent to the ratio of the solubility of the diffusant in the SC medium
with respect to the aqueous medium at each of the separating barriers. Therefore, by
substituting the SC partition coefficient relationship into the second part of equation (2.7),
the final form of the flux equation with respect to the concentrations in the aqueous regions
is obtained. This form of the flux equation holds the advantage of requiring the aqueous
concentrations, which are easily obtained compared to the concentrations in the SC [25].
From equation (2.8), it is evident that any modifications to the SC permeability are
related to the diffusivity across the SC. Permeability is a rate phenomenon that contains
contributions from partitioning and intermembrane diffusion. The diffusivity through the
SC follows Non-Stokesian behavior, as the SC is not fluid. Diffusion through the SC is
similar in concept to diffusion through a polymer matrix, but its permeability varies
between individuals based on genetics, temperature, lifestyle and body part. Therefore,
temperature impacts SC permeability both from the Stokesian diffusion diffusivity term
and the exponential Arrhenius term. An increase in temperature results in an increase in
SC permeability and drug solubility because there is an increase in free volume and its
formation. This is also expressed in the lipid fluidization or melting around the corneocytes,
which permits increased movement in the lipid medium [31].
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2.7 Case Studies – Supporting Research
At this point, computational diffusion studies of TDD are quite scarce. Most research and
testing on skin patches relies on clinical trials including those for dosage determination,
which poses high risk to the test subjects. The TDD clinical trial reports primarily rely on
questionnaire data collected from the subject and their respective blood tests. This poses
several issues in obtaining an exact analysis of any skin patch that is released into the
market, as skin permeability and individual sensitivity to drug uptake varies between
individuals. As skin permeability is quite variable and side effects are possible, clinical
trials cannot be completely eliminated but they can be designed in a safer manner by
computational estimation of the drug’s diffusivity. Three case studies will be discussed.
The first Nicotine patch analysis is qualitatively based on clinical trials, whereas the second
research will discuss the computational determination of the diffusivity of nicotine
diffusing through the skin patch copolymer matrix. Finally, the clinical trial report for the
SYNERA Heated Lidocaine Tetracaine patch will be discussed, as it is the patch being
tested in this study.
2.7.1 Nicotine Patch
As mentioned above, most pharmacokinetic analyses of TDD patches are rarely
quantitative. One such analysis was used to compare the diffusion profile of the 21-mg/24hour NiQuitin Patch (Nicoderm CQ in the USA and Nicabate in Australia) with that of the
Nicorette Invisi 25-mg/16-hour patch. The test subject pool consisted of fifty smokers that
smoke 11-40 cigarettes daily, twenty one female and twenty nine males. The NiQuitin
patch is applied for twenty four hours, with an initial dose of 21 mg. The Nicorette Invisi
patch is prescribed for sixteen hours of application, with a starting dose of 25 mg. The

28

subjects received both forms of treatment consecutively, with half of the subjects starting
with the NiQuitin treatment followed by the Nicorette treatment while the other twenty five
subjects went through the treatments in the reverse order. The control was the NiQuitin
patch worn for sixteen hours rather than the prescribed twenty four hours. The
pharmacokinetic profile for the TDD treatments was obtained from blood samples drawn
from the patients up to thirty two hours post-initiation of treatment. All patient incidents
were reported via a questionnaire [32].

Figure 2.8 Mean plasma nicotine concentrations during exposure to the NiQuitin and
Nicorette Invisi transdermal Nicotine systems.
Deveaugh-Geiss, Angela M., L. H. Chen, M. L. Kotler, L. R. Ramsay and M. J. Durcan.
"Pharmacokinetic Comparison of Two Nicotine Transdermal Systems, a 21-mg/24-hour Patch and a 25mg/16-hour Patch: A Randomized, Open-label, Single-dose, Two-way Crossover Study in Adult
Smokers." Clinical Therapeutics 32.6 (2010): 1140-148.

The results indicated that the NiQuitin Patch provided the larger overall nicotine
exposure, as indicated by its larger area under the curve (AUC) in Figure 2.8. Also, the
maximum plasma nicotine concentration was higher for the NiQuitin patch and was
reached faster than for the Nicorette patch, which exhibited a more gradual nicotine release
profile without the initial concentration spike seen for the NiQuitin patch. Most patients
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reported adverse events for both treatments. The adverse events were classified as primarily
mild, as they were attributed to irritation due to the patch itself and some dizziness, with
one subject requiring cessation of treatment. It was not mentioned which of the treatments
led to the latter case nor did the article indicate if it was the patient’s first or second round
of TDD treatment. Individual variation in response to medication exemplifies the need to
computationally analyze TDD treatments prior to clinical trials. Furthermore, the
diffusivity differences between both patches were neither extensively analyzed nor were
they calculated for the initial increase in nicotine plasma concentration for both patches.
Computational analysis of the diffusivity through the polymer matrix for both patches
could put into perspective the significance of their individual design parameters and their
implications [32].

2.7.2 Computational Determination of Diffusivity
The article New Screening Methodology for Selection of Polymeric Matrices for
Transdermal Drug Delivery Devices [1] is the only research directed at the computational
analysis of a drug diffusing through a polymer matrix in the skin patch. In this case, the
nicotine patch was used to validate the results. The methodology in this research is the
basis for the research discussed in this thesis, except that the skin patch analyzed is the
SYNERA local anesthetic heated lidocaine-tetracaine patch. As this skin patch contains a
diffusion enhancing component and there are two diffusing molecules, some adjustments
will be made to the modified Duda-Zalinsky equation (DZE) constructed by Falcone in his
computational analysis of the diffusivity of nicotine [1].
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Diffusion through the TDD patch can be modeled as diffusion through a planar
surface. Crank provided the following solution for the concentration profile in planar
diffusion:

⁄

(2.7)

2√
When

0.5

(2.8)

In equation (2.7), C is the solute concentration, D is the diffusivity, t is the time, x
is the diffusion length. The relationship in equation (2.8) for the ratio of the solute
concentration (Mt) at time t with respect to the initial concentration M∞ holds true for the
following boundary condition: concentration at time t is equal to or less than half the initial
concentration [1].
For the purpose of analysis of a drug diffusing through a polymer matrix, the
diffusion process must be modeled by the free volume theory. This model describes
diffusion as a mechanical model that involves concurrent exchange between the free and
occupied volumes. Therefore, the specific gap free volume in equation 2.5 is calculated
based on the ratio of the molar gap free volume (

) with respect to the molecular

contribution of each of the constituents (the ratio of the individual weight fractions, wi,
with respect to their molecular weights, Mi, polymer and drug) to the system:

(2.9)
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Equation (2.9) was incorporated into Vrenta and Duda’s equation (equation (2.5))
to form equation (2.10). Since in the nicotine patch, nicotine diffuses through a block
copolymer matrix, the second weight fraction in the denominator of equation (2.9) is
multiplied by the ratio of the weight fraction of each of the polymers in the matrix divided
by their molecular weight. Furthermore, the effect of the copolymer matrix was carried
over to the calculation of the solvent critical molar volume jumping unit with respect to the
polymer jumping unit that is designated as ε (eq. (2.11)) [1].

(2.10)

⁄

(2.11)

4
3
4
3
3
4

(2.12)

One of the advantages of this methodology lies in the usage of the hydrodynamic
radius of the drug, as the critical volume for diffusion relies on the resulting effective
volume due to the rotation of the molecule about its center of gravity. The molecule’s
effective center of rotation does not necessarily lie at the center of the molecule and can be
impacted by secondary interactions of the molecule’s functional groups. The
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hydrodynamic radius (R0) is obtained by relating the spherical molar volume of the drug
and its density, which should give an over estimation of the actual molar volume of the
drug as it is representative of the radius that stems from the rotation of the molecules
(equation (2.12)). Energy values were obtained through the Tonge and Gilbert equation.
Diffusivity values, obtained for nicotine, based on these computation were
compared to diffusivity values obtained from the concentration profile of the investigated
nicotine patch. The concentration profile for the nicotine patch was generated from UV
spectrophotometry absorption readings of samples extracted periodically from a Franz-Cell
apparatus, which had the nicotine patch clamped to its cell top opening thereby permitting
nicotine diffusion (Figure 2.9) [1].

Figure 2.9 Components of PermGear’s Franz Cell Apparatus.
PermeGear. http://www.permegear.com/franzatfaqs.htm

As can be seen in the results in Figure 2.10, below the calculations for the
cumulative amount released, the product of the diffusivity and the time point in the
diffusion process, for both experimental and calculated values are close with the percent
error increasing with respect to the diffusion time. The final diffusivity results, summarized
in Table 2.3, show that the calculated diffusivity is of the same order of magnitude as the
experimental diffusivity, with an over estimation of approximately 17%. To emphasize the
significance of this result, the diffusivity values obtained were compared to the diffusivity
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values for nicotine provided in the literature, which stated that the diffusivity range is
between 10-9-10-10 cm2/s. Therefore, this computational model is fitting to describe
diffusion through polymer matrices in TDD patch systems [1].

Figure 2.10 Cumulative release comparison for the experimental and estimated
nicotine diffusivity values.
Falcone, R., Jaffe, M. and Ravindra, N.M., New screening methodology for selection of polymeric
matrices for transdermal drug delivery devices, Bioinspired, Biomimetic and Nanobiomaterials, Volume
2 Issue BBN2, p. 65-75, 2013.

Table 2.3 Comparison between experimental and calculated nicotine diffusivity
values

Falcone, R., Jaffe, M. and Ravindra, N.M., New screening methodology for selection of polymeric
matrices for transdermal drug delivery devices, Bioinspired, Biomimetic and Nanobiomaterials,
Volume 2 Issue BBN2, p. 65-75, 2013.

The method of computation of diffusivity, used for nicotine, is the basis for the
procedure used in the research discussed in this thesis. In this research, Galen
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Pharmaceitical’s Heated Lidocaine/Tetracaine local anesthetic patch is analyzed, with
added corrections to the diffusivity equation proposed by Falcone so as to account for the
impact of the diffusion enhancement on the diffusivity of the solutes.
2.7.3 SYNERA Heated Lidocaine-Tetracaine Patch
Lidocaine has been used for topical anesthesia since the 1980’s in various forms. It has
evolved over several cycles from a cream to a TDD patch where the lidocaine active is held
as part of a eutectic mixture. Some of the hallmarks of the development of this local
anesthetic include the following forms: cream in the form of a submicron emulsion (SME),
lidocaine/prilocaine eutectic mixture in regular cream, lidocaine/tetracaine eutectic
mixture in regular cream, lidocaine/tetrcaine eutectic mixture in SME cream,
lidocaine/epinephrine patch (Iontocaine,1995), lidocaine patch (Lidoderm, 1999),
lidocaine/ultrasound patch (SonoPrep, 2004) and finally, lidocaine/tetracaine heated patch
(Synera, 2005 – the gold standard).
Eutectic mixtures are normally mixtures of two components that together develop
different physicochemical properties compared to their separate pure forms, which is due
to moderate molecular interactions between the individual constituents. These properties
do not impact the individual constituents’ inherent molecular orientation, rather some of
their characteristics are modified. As an example, the eutectic mixture’s melting point is
significantly lower than either constituent’s individual melting point, which poses the
advantage of lowering the processing temperature of either of the constituents if called for.
In the case of the lidocaine/prilocaine eutectic mixture, the melting point of the
system is 32°C while lidocaine’s melting point in its pure form is 68°C. As this melting
point is slightly below skin surface temperature, the lidocaine anesthetic assumes a molten
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form upon contact with the skin. The eutectic mixture’s physical properties facilitate more
rapid skin penetration of lidocaine with respect to its pure form. Therefore, eutectic
mixtures have been found to enhance transmembrane diffusion.
In the past, the lidocaine anesthetic cream has been formulated as a eutectic mixture
with prilocaine; but studies have shown to exhibit competitive diffusion properties.
Lidocaine’s diffusion is more influenced by the partition process, whereas prilocaine’s
diffusion is more influenced by the transport process. A diffusion study of the
lidocaine/prilocaine eutectic mixture showed that maximum skin permeation occurs for
mixture compositions where the solid and liquid phase are not at equilibrium. This is
indicative of questionable stability of the eutectic mixture formulation.
The latter observation was corroborated by a thermal analysis that compared the
stability of the lidocaine/prilocaine eutectic mixture with the stability of the
lidocaine/tetracaine eutectic mixture. The authors found that the lidocaine/tetracaine
eutectic mixture’s crystallization peaks, observed through modulated temperature
differential scanning calorimetry (MTDSC), are in close temperature proximity to the
lidocaine/prilocaine eutectic mixture’s crystallization peaks. This implies that the
lidocaine/tetracaine eutectic mixture contains more intermolecular interacting groups,
thereby preventing crystallization out of formulation of either constituent in the binary
mixture. It is evident from the molecular structures of lidocaine and tetracaine (Figure 2.11)
that both molecules have the same functional groups with some structural differences and
comparable molecular weights, which explains their similar physical properties.
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Figure 2.11 Molecular structures of lidocaine and tetracaine labeled A and B,
respectively.

The Synera heated patch (Figure 2.12) was compared in a clinical trial setting to
the lidocaine/prilocaine cream (EMLA). The Synera patch contains a eutectic mixture of
70 mg of lidocaine and 70 mg of tetracaine, with a suggested application time of at least
twenty minutes – preferably thirty minutes, prior to local procedure. The lidocaine
prilocaine cream provides with a 25 mg/mL dosage and should be applied one hour prior
to local procedure. The Synera patch contains an iron nanoparticle and carbon heating pod
on the top layer of the patch that is covered by a perforated covering, which exposes the
heating pod to oxygen upon opening of the packaging and induces an exothermic oxidation
of the iron nanoparticles that locally raises the skin surface temperature by 5°C. As
previously discussed, the added heating component provides additional energy to the
diffusing particles as well as promotes fluidization of the lipid matrix in the SC that could
explain the shorter anesthetic application time.
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Figure 2.12 Layer by layer breakdown of the Synera heated lidocaine/tetracaine heated
patch.
Sawyer, J., S. Febbraro, S. Masud, M. A. Ashburn, and J. C. Campbell. "Heated Lidocaine/tetracaine
Patch (SyneraTM, RapydanTM) Compared with Lidocaine/prilocaine Cream (EMLA(R)) for Topical
Anaesthesia before Vascular Access." British Journal of Anaesthesia 102.2 (2009): 210-15.

The investigation study group consisted of 82 healthy adults (37 males, 45 females)
with varying skin types that received both anesthetic treatments simultaneously in two
separate, but equivalent, skin locations. Both anesthetics were applied for 10, 20, 30 and
60 minutes prior to a vascular access procedure. Pain intensity was assessed by the subjects
using a 100 mm visual analogue scale (VAS), with skin or any other side effects being
visually inspected. The reported median VAS score was significantly lower for the Synera
patch compared to the lidocaine/prilocaine cream for all time points leading up to thirty
minutes; yet similar VAS scores were given to both anesthetics at the 60 minutes time
point. Overall, it was deduced that the Synera lidocaine/tetracaine patch is more effective
than the lidocaine/prilocaine cream due to it faster penetration. It is important to emphasize
the significance of a computational model for this type of investigation, as opinion based
pain evaluations are very individual because different people have different pain thresholds
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and tolerances. Therefore, as this comparison validates the advantages of the Synera patch,
it is of purely qualitative value.
Anesthetics have been shown to be of high skin penetration efficacy with skin
fluidization properties. This is counterintuitive as anesthetics primarily perform their
function by inhibiting protein-mediated transport processes that take part in the body’s
signaling process. Yet further investigation elucidated that, in addition to the anesthetic’s
inhibitory character, it also behaves similarly to a plasticizer in a polymer. Plasticizers are
small molecules that disrupt intermolecular interactions in polymers, thus reducing
polymer brittleness and increasing its ductility with respect to a certain temperature. In
effect, this change in physical properties results from the reduction in the glass transition
temperature of the polymer. Therefore, plasticizers serve to increase diffusion rates in
polymers. Similarly, at high concentrations, anesthetics actually increase membrane
permeability. Anasthetics fluidize lipid bilayers and biological membranes, which signifies
that the Synera heated lidocaine/tetracaine patch has an additional inherent diffusion and
permeability enhancer upon SC saturation. Despite anesthetic potency being an
equilibrium phenomenon that relies on anesthetic partitioning, membrane permeability is
also influenced by the actual intermembrane diffusion.
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CHAPTER 3
EXPERIMENTAL APPROACH

3.1 Impact of Heat/Composition
Computational research in this area has focused on the standard skin patch, to utilize a
modified version of the DZE to predict drug diffusion in a noninvasive manner prior to
testing of patches. It is of great importance to validate these modifications for other
formulations of patches with varying matrices, drug actives and especially diffusion and
permeability enhancers. Diffusion and permeability enhancements are of significant value
for future formulations, as they will not only improve the diffusion efficiency of the drug,
but will also provide an opportunity for the utilization of TDD to a wider range of
therapeutics. As discussed extensively in the previous chapter, the heat enhancement in the
Synera patch adds energy for partitioning of both lidocaine and tetracaine and it helps to
fluidize the SC by liquefying the lipid components in the polymer matrix and facilitating
less resistive diffusion paths. Furthermore, the Synera patch involves a eutectic mixture as
its active component as opposed to a single drug active.
The free hole volume is a function of the structure of the polymer matrix and
diffusant occupying volume in relation to the reference temperature relative to the glass
transition temperature. Equation (3.1) shows Fierro et al.’s method of computing the free
volume.

(3.1)
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K11 and K21 are free volume parameters for the active components, which can be retrieved
via nonlinear regression of the equation for the base ten logarithm of the difference in
viscosity between the glass transition and reference temperatures [35]. K12 and K22 are the
free volume parameters for the polymer matrix. T is the reference temperature and wi and
Tgi are the weight fractions and glass transition temperatures of component “i”, where the
subscript 1 denotes the drug active and 2 denotes the polymer matrix. It is important to
note in this equation that only one active at a time is included in this calculation. This is
acceptable because the diffusion of drug actives is not codependent [1].
K11, K21 and K12, K22 are related to the Williams-Landel-Ferry (WLF) constants,
C1, C2. K12 is related to the critical molar volume and the overlap factor. In combination
with a nonlinear regression with respect to the Doolittle equation for viscosity, K12, can be
used to solve for the overlap factor. The WLF constants for the polymer were retrieved
from linear regression of values found in the literature for varying PVA concentrations
[36]. The glass transition temperature for lidocaine and tetracaine was calculated by a
group contribution method (equation (3.2)). This method computes the product of the
molecular weight and “glass transition temperature” contributed by individual parts of the
polymer backbone (denoted “i”) and side chains (denoted “j”), distributed over the entire
molecular weight [37].

1

(3.2)
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3.1.1 Modifications to DZE
The energy and viscosity components of the diffusivity calculations performed in this
research are in agreement with those performed in the computational analysis of nicotine
discussed in Section 2.7.2, with a few modifications. In this case, the solute is a binary
system and the matrix is being treated as one polymer component. Furthermore, the
temperature analysis will consider the additional 5°C added by the Synera skin patch
heating component.

3.1.2 Composition Calculations
The composition of the drug actives was taken as 1:1 as listed in the specifications of the
drug. Based on the list of ingredients of the patch, the primary polymer contribution to the
diffusion membrane was attributed to polyvinyl alcohol. TGA was used to assess the
weight contribution of the polymer matrix to the TDD patch system. Due to the proprietary
nature and confidentiality of this patch, these results and analyses will not be discussed in
this thesis.

3.1.3 Energy Calculations
The energy calculation was computed based on the Tonge and Gilbert computation,
equation (3.1) [33]. To obtain the partitioning energy (E*) involved in either of the drugs’
diffusion through the polymer matrix, the cohesive energy density (δ) of lidocaine
tetracaine was computed based on equation (3.2). The cohesive energy density is also
representative of the constituent’s solubility. The enthalpy of vaporization (H), subtracted
by the product of the ideal gas constant (R) and the temperature in kelvin (T), represents
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the cohesive energy of the molecule that is stored in its own molecular volume unit (VM).
The cohesive energy density for PVA was obtained from the literature. Equation (3.3)
shows the Yamada and Gunn equation [34] for the molecular volume at the testing
temperature, as the cohesive energy of the molecule varies with temperature. All properties
denoted with the subscript “c” represent the critical properties of the molecule, at which
point condensation of vapor does not occur despite temperature elevation.

∗

2.8377

0.8988 ln log

(3.1)

(3.2)

,

0.29056

⁄

0.08775
1,

0.7

(3.3)
(3.4)

;
∆

ln

1

1

9
128

1

6

1

(3.5)

(3.6)

The saturated liquid molar volume requires the calculation of the acentric factor
(equation (3.4)), a measure of corresponding state for saturated hydrocarbons [38]. All the
properties denoted with the letter “r” refer to the reduced value of that property. This
equation is only valid for the reduced saturated vapor pressure (prsat) at a reduced
temperature value of 0.7. The Clausius Clapeyron equation (equation (3.5)) for real gases
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was used to calculate the saturated vapor pressure. This calculation was based on the
pressure and temperature data at room temperature from the literature. The ideal gas
Clausius Clapeyron equation has an added correction factor, Z, called the compressibility
factor. The compressibility factor was estimated with the Berthelot equation
(equation (3.6)).

3.2 Materials
Experimental process:
1. PermGear Franz-Cell apparatus (6-cell apparatus).
Table 3.1 Cell Dimensions (by cell number, from right to left)
Cell no.
1

Volume
(mL)
11

Top Inner
Diameter (cm)
1.5

2

10.6

1.5875

3

11.6

1.524

4

12.6

1.60

2. Hot water bath.
3. Water pump.
4. Synera skin patches.
5. Saline solution.
6. UV spectrophotometer.
7. 500 mg/L lidocaine in water stock solution.
8. 100 mg/L tetracaine in water stock solution.

44

9. Thermocouple.
10. IR camera.
For the experiments, a Franz cell apparatus was employed with a water pump for
temperature control of the system. Saline served as the diffusion media in the cell body. As
the patches were quite large, the clamp on its own was enough to keep the patch in place.
Sample analysis was conducted via a UV spectrophotometer. Stock solutions prepared for
the calibration curve were made of dilutions of 500mg/L lidocaine in de-ionized water and
100mh/L tetracaine in de-ionized water solutions.

3.3 Franz-Cell Apparatus
The Franz-Cell was connected to a hot water pump to maintain the temperature of the
system. The water flows between the outer walls of the cell, while the inner cell contains a
small magnetic stirrer set underneath a coil to induce constant mixing when the apparatus
is turned on. The Synera patch was clamped without a cap, as its dimensions permit this
construct. The cell bodies should be filled completely with saline and must form a meniscus
in the cell top, so as to ensure constant surface contact of the patch diffusion site and the
aqueous solution. Periodic samples of approximately 1 mL were taken at four different
time points through a long needle that extends into the cell body via an inlet opening. To
prevent disruption of the diffusion system, an equivalent volume of saline was added into
the cell body after each sample extraction.
A calibration curve was set up from serial dilutions of the lidocaine and tetracaine
stock solutions. 0.1 M hydrochloric acid was added to the stock solutions along with pH
buffer no. 6, so as to promote solute dissolution. Based on literature values, the peak UV
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absorbance wavelengths are 262±1nm [39] and 310±1nm [40] for lidocaine and tetracaine,
respectively. As Beer’s law states, for small absorbance values (between 0.01-1), the
absorbance is linearly related to the sample concentration, diffusion length and extinction
coefficient of the sample. Therefore, the linear regression equation obtained from the
calibration curve for the stock solution and its dilutions provides a direct relationship to the
active concentration in the sample. The diffusion profile for the drug is made up of a plot
of the generated concentrations with respect to their sampling time. The concentration
profile for a skin patch is linear until the concentration plateaus. The slope of the line prior
to the leveling of the concentration is the diffusivity. For this wavelength range, quartz
cuvettes must be used to obtain accurate readings. Table 3.2 lists the dilutions of the stock
solutions, where C0 is a concentration of 100 mg/L.
Table 3.2 Serial Dilution Concentrations for Lidocaine and Tetracaine’s Calibration
Lidocaine Concentration

Tetracaine Concentration

5 C0

500mg/L

C0

100 mg/L

3.25 C0

325 mg/L

0.9 C0

90 mg/L

2.5 C0

250 mg/L

0.75 C0

75 mg/L

1.75 C0

175 mg/L

0.5 C0

50 mg/L

C0

100 mg/L

0.25 C0

25 mg/L

0.75 C0

75 mg/L

0.10 C0

10 mg/L

0.5 C0

50 mg/L

0.25 C0

25 mg/L

0.10 C0

10 mg/L
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3.4 Temperature Corroboration
Temperature corroboration in this experiment is important because it provides information
on the functionality of the patch and the temperature stability of the diffusion system,
whose temperature is maintained by the pumping of the water from the hot water bath.
Thermocouples were placed between the cell body and its holder so as to record the
temperature of the system. An IR camera is used to verify that the 5°C temperature increase
reported by the manufacturer is accurate and persistent throughout drug administration.
Based on the difference in the colometric temperature in the area of the patch compared to
the temperature further down in the cell body, the induced temperature increase can be
validated. As the SC is less than 3 µm in thickness, the temperature penetration depth is
not of significance.
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CHAPTER 4
RESULTS AND DISCUSSION

4.1 Computational Results
Table 4.1 shows the calculated hydrodynamic radius, the glass transition temperature and
its corresponding viscosity for lidocaine and tetracaine. Table 4.2 is divided into three
testing temperatures for lidocaine and tetracaine. As can be seen, tetracaine has a larger
activation energy, due to its larger molecular weight. Initially, the impact of the heating
pod was thought to have a large impact on the energy of the actives (Table 4.2). Based on
the tabulated values with respect to temperature, the increase in additional available energy
is not significant for such temperature differences.

Table 4.1 Calculated Hydrodynamic Radius, Tg and the Corresponding Viscosity for
Lidicaine and Tetracaine
Tg (K)
µ (Pa-s)
R0
219.74 0.05594947
3.9588E-10
Lidocaine
268.105 0.013004086
3.9588E-10
Tetracaine

The viscosity decreases with increasing temperature, but the results show that for
all temperatures they are of the same order of magnitude. Therefore, their impact on the
diffusivity is similar.
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Table 4.2 Energy, Viscosity, Free Volume and Stokes Einstein Diffusivity Multiplier
for Lidocaine and Tetracaine with Respect to Temperature Setting
Property
T=303.15 K E (J)
µ (Pa-s)
D0 (m/s^2)
T=308.15 K E (J)
µ (Pa-s)
D0 (m/s^2)
T=310.15 K E (J)
µ (Pa-s)
D0 (m/s^2)

Lidocaine
38678.63
0.003716002
1.50942E-06
38713.12
0.003309274
1.7229E-06
38726.97
0.003162641
1.81448E-06

Tetracaine
43147.55
0.00455435
1.03294E-06
43172.64
0.003998203
1.19602E-06
43182.705
0.003799714
1.26667E-06

Table 4.3 summarizes the WLF factors that are used to calculate the free volume
parameters for the free volume. Lidocaine and tetracaine have similar critical molar
volumes, which are less than a third of PVA’s critical volume. Therefore, it may be deduced
that the primary contribution to the overlap factor and the primary occupier of the free
volume is PVA. The diffusivity values obtained with the DZE will not be extensively
discussed for this system, as they were off by about two orders of magnitude with respect
to the experimental diffusivities. This is attributed to the free volume calculations that need
further fine tuning.

Table 4.3 WLF Constants and Critical Molar Volumes of PVA, Lidocaine and
Tetracaine

PVA
Lidocaine
Tetracaine

C1
17.4
1.22534
1.7934
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C2
V* (cm3)
51.6
313.8
3.69403 89.79595
4.76435 94.26971

4.2 Experimental Results
In order to quantify the concentrations of the samples taken from the Franz Cell apparatus
at different points in the diffusion process, a UV absorption calibration curve for different
known concentrations of lidocaine was set up. Pure lidocaine and tetracaine exhibit peak
absorbance values at wavelengths of 262±1 nm and 310±1 nm, respectively. In this
particular UV spectrophotometer, the absorbance peaks were observed at 262.5 nm and
310.5 nm for lidocaine and tetracaine, respectively.
Lidocaine Calibration Curve
(λ = 262.5 nm)

Tetracaine Calibration Curve
(λ = 310.5 nm)

1.2

1.2

Absorbance

1
0.8
0.6
0.4

y = 0.0108x ‐ 0.0092
R² = 0.9981

1

Absorbance

y = 0.002x ‐ 0.0038
R² = 0.9999

0.2

0.8
0.6
0.4
0.2

0
0

0
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100
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Figure 4.1 Lidocaine (left) and tetracaine (right) UV absorbance calibration curves.
According to the Beer-Lambert law, for absorption values between 0.01-1 (i.e. low
concentrations), there is a linear relationship between the concentration and absorbance
(equation (4.1)). The absorbance is related to the sample concentration (C) multiplied by
the extinction coefficient of the sample (ε) and the path length of the light passing through
(L), which is simply the width of the cuvette (10 mm in this case). This relationship held
true for the solution concentrations plotted in Figure 4.1, that display an R2 value for both
linear regression lines close to one.

50

(4.1)

Figure 4.2 Franz Cell system temperature (°C) corroboration on the thermocouple.
As can be seen in Figure 4.2, the temperature was held stable throughout the
diffusion process, with mild decrease in the last ten minutes. As will be discussed below,
by the end of the first 5-10 minutes (temperature pending) the drug concentration peak is
reached and maintained through the end of the run. The IR images (Figure 4.3, 4.4) confirm
that the company statement that the heating pod provides a local increase in temperature of
5°C is correct.
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Figure 4.3 Thermal image of cells 3 and 4* during the diffusion run (side view).
* Cell 4 is the left cell and it is the nonheated control.

Figure 4.4 Thermal image of cells 1-4* during the diffusion run (top view).
* Cell 4 is the left cell and it is the nonheated control.

The side view (Figure 4.3) serves to show the heat diffusion distance, as there is a
heat gradient throughout the length of the cell body where the maximum temperature is at
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the top and the minimum is at the bottom. Despite this gradient it may be assumed that
when the Synera patch is applied the local SC temperature matches the maximum
temperature, which is the critical determinant of the drug penetration. Figure 4.4 confirms
that the control did not experience the oxidation reaction as a result of obstructing the top
openings with tape. The temperature difference was further confirmed by the color
difference between the top view of the patch that was used as the control and the rest of the
cells.
Figure 4.4 below contains the lidocaine diffusion profile at 30°C, 35°C and 37°C.
The diffusion with respect to time at 30°C reaches its peak cumulative release at after 10
minutes, whereas this time period is shortened to 5 minutes for diffusion at 35°C and 37°C.
At 30°C the control, the patch that did not undergo oxidation, exhibited a significantly
reduced supplied dosage. Yet for the higher testing temperature, the peak concentration is
similar with respect to the control. As can be seen in Figures 4.4A and 4.4B, the results
collected for cell 3 peak at twice the lidocaine released, which compared to the rest of the
cells. This is the reason that the tests results in Figure 4.4 C were only performed on the
first two cells. The experiments in Figures 4.4A and 4.4B were performed on the same day
and the discrepancy was correlated to a faster spin rate of the magnet in cell 4, which
initially went unnoticed. A research conducted on the Franz Cell apparatus showed that
stirring speed impacts the amount of time a dye gets dispersed in the Franz cell and the
time it takes it to reach up the sampling arm. On the other hand, too high of a stirring speed
may result in vortexing, which can disrupt the diffusion cell [41].
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Figure 4.4 Cumulative accumulation of lidocaine with respect to time at
A)30°C=303.15 K, B) 35°C=308.15 K and C) 37°C=310.15 K.
Figure 4.5 displays the mass of accumulated tetracaine in the cell body. A similar
diffusion pattern to that of the lidocaine was observed, with peak accumulation occurring
at the 10 minutes and 5 minutes time point for 30°C and 35-37°C, respectively. The same
discrepancy with respect to cell 4 was observed in the tetracaine results, as well. It is
important to note that despite the initial lidocaine and tetracaine dosages being identical in
the patch regimen, approximately double the amount of lidocaine compared to tetracaine
diffuses into the cell. This can be explained by lidocaine’s lower octanol:water partition
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ratio of 182 at pH 7.3 compared to tetracaine’s higher partition ratio of 5370 at pH 7.3 [42].
As the cell media is saline, 0.9% NaCl aqueous solution in water, tetracaine’s hydrophobic
character results in a hindered diffusion of tetracaine. The Synera patch prescribing
information discussed its clinical trials that revealed that approximately 1.7 mg and 1.6 mg
of lidocaine and tetracaine, respectively, were absorbed by the subject [43]. The mass of
lidocaine was substantially below the maximum dose released in the Franz cell, which can
be explained by the skin barrier that is posed by the skin. In contrast, the reported peak
accumulation for tetracaine was slightly higher than the experimental results in Figure 4.5
C. This may be attributed to tetracaine’s higher partition ratio that compensates for its
reduced diffusion into aqueous solution, by increasing its probability of diffusing through
the hydrophobic SC barrier.
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Figure 4.5 Cumulative accumulation of tetracaine with respect to time at
A)30°C=303.15 K, B) 35°C=308.15 K and C) 37°C=310.15 K.
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Table 4.4 Franz Cell Diffuivity Results

Temperature

Cell no.

30°C

1
2
3
4, Control
1
2
3
4, Control
Cell 1
Cell 2
1, Control

35°C

37°C

Lidocaine
Diffusivity
(cm2/s)
5.50208e-07
6.30504e-07
9.65049e-07
1.87482e-07
9.48895e-07
1.18473e-06
2.70498e-06
1.30702e-06
6.53372e-07
6.16912e-07
9.8185e-07

Tetracaine
Diffusivity
(cm2/s)
3.68461e-09
3.96706e-09
5.88052e-09
7.84265e-10
5.73027e-09
7.30005e-09
2.648e-08
7.73061e-09
4.44946e-09
5.75549e-09
8.57112e-09

Table 4.5 Standard Deviation Between Cell 1 and 2 Diffusivity Values and Average
Drug Accumulation

T (°C)
30
35
37

Standard Deviation of the
Diffusivity
Lidocaine
Tetracaine
5.67775e-08
2e-10
1.66763e-07
1.11e-09
2.57814e-08
9.24e-10

Average Maximum
Accumulation (mg)
Lidocaine
Tetracaine
3.9432
0.732185
3.5457
0.692926
1.9292
0.530981

Table 4.4 shows that the diffusivity of lidocaine is greater than that of tetracaine by
two order of magnitude, as the cell medium is aqueous. As can be seen in Table 4.5, the
standard deviation between cell 1 and cell 2 is insignificant. Therefore, diffusion results
for these cells may be regarded as consistent duplicates for the purpose of analysis.
Comparison of the diffusivity results with respect to the control showed that the added heat
enhanced diffusion below 35°C. Above this temperature, diffusivity values in the Franz
Cell apparatus were not enhanced (Table 4.6). This may be attributed to the eutectic

56

mixture’s melting point, which is 32°C. As room temperature is approximately 25°C, it is
deduced that the heating components ensures that the eutectic mixture is at an optimal
diffusion state, liquid, upon application of the patch. Although normal body temperature
suffices to melt the eutectic mixture, the passive heat transfer would take longer without
the added heating component. Furthermore, the added heat may assist in increasing skin
permeability.

Table 4.6 Comparative Analysis of the Average Diffusivity of Lidocaine (top) and
Tetracaine (bottom) to the Non-Oxidated Control

T (°C)
30
35
37

T (°C)
30
35
37

Lidocaine
Control Diffusivity
Average Diffusivity
(cm²/s)
(cm²/s)
1.87482E-07
5.90356E-07
1.30702E-06
1.06681E-06
9.8185E-07
6.35142E-07
Tetracaine
Control Diffusivity
Average Diffusivity
(cm²/s)
(cm²/s)
7.84265E-10
3.82584E-09
7.73061E-09
6.51516E-09
8.57112E-09
5.10248E-09

57

% Difference
68.24%
-22.52%
-54.59%

% Difference
79.50%
-18.66%
-67.98%

CHAPTER 5
CONCLUSION

The results showed that the temperature increase did not have a strong impact on the
diffusive properties of lidocaine and tetracaine through the polymer membrane. Rather, the
added temperature serves to facilitate better skin penetration by adjusting skin permeability
and the physical state of the eutectic mixture. Further research is crucial for further
specification and broadening of patch applications to include therapeutics that have charge
or are larger than 500 Da. Such therapeutics include liposomal drug delivery, magnetic
nanoparticle assisted drug delivery and gene therapy. Converting these treatments into
TDD patches will not only alleviate the experience involved with these treatments, but it
will help to improve their efficacy due to the sustained release feature of the skin patch.
This pre-clinical trial, utilizing a scientific approach via computational analysis, serves as
a platform for safer clinical trials.
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APPENDIX A
COMPARISON OF THE CUMULATIVE ACCUMULATION WITH RESPECT
TO THE DIFFUSION CONTROL

The following table shows that the difference in diffusivity is negligible above 30°C
because the melting point of the eutectic mixture is 32°C. The percent difference in
accumulation, with respect to the control, for lidocaine and tracaine correspond to each
other. This trend is also observed in the diffusivity comparative analysis in Table 4.6.

Table A.1 Comparative Analysis of the Average Accumulation of Lidocaine (top) and
Tetracaine (bottom) to the Non-Oxidated Control
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